Search

Abstract Neoadjuvant immunochemotherapy (NAIC) achieves superior clinical benefits over neoadjuvant chemotherapy (NAC) in multiple types of human cancers, including gastric adenocarcinoma (GAC). However, it is poorly understood how the malignant epithelial cells and tumor immune microenvironment (TIME) might respond distinctly to NAIC and NAC that underlies therapeutic efficacy. Here treatment‐naive and paired tumor tissues from multiple centers were subjected to pathological, immunological, and transcriptomic analysis. NAIC demonstrated significantly increased rate of pathological complete response compared to NAC (pCR: 25% vs. 4%, p

Introduction: The management of gastric cancer in advanced stages, which is the second most leading cause of cancer mortality in the world, has evolved very little. Surgical resection remains the mainstay of treatment and can cure patients with early-stage cancer. The survival rate of patients with advanced resectable-gastric cancers, however, remains poor despite new treatment strategies. A better understanding of the molecular basis of cancer has contributed to the development of rationally designed molecular targeted therapies, which interfere with the signalling cascades involved in cell differentiation, proliferation and survival. Aim: To evaluate the expression of HER2 (Human epidermal growth factor receptor 2) by Immunohistochemistry (IHC) in intestinal and diffuse type gastric carcinomas, in and around Kanchipuram, Tamil Nadu, India. Materials and Methods: Fifty cases (31 males, 19 females) were selected which includes 30 cases of resected gastric carcinoma specimens and 20 cases of endoscopic guided biopsies diagnosed as gastric carcinoma in the Department of Pathology, in Meenakshi Medical College and Research Institute (MAHER), Enathur, Kanchipuram, Tamil Nadu which is a teaching medical college and hospital in southern part ofIndia from January 2012 to July 2014 for a period of two and half years. All the cases that were received during the study period that-fulfilled the inclusion and exclusion criteria were included in the study. All cases were analysed for their expression of HER 2/Neu protein antigen by Immunohistochemical staining in this study. The scoring criteria established by an international consensus panel of oncologists and pathologists was followed. Breast carcinoma tissue positively expressing HER2 was used as the positive control. We considered only those tumours expressing 3+positivity as those expressing HER2. Results: HER2 score was significantly higher in intestinal type gastric carcinomas. Of the total 26 cases expressing the HER2 protein, 81% (21/26) were of intestinal type Vs 19% (5/26) that of diffuse types (p=0.007). Also, no statistical difference was found between other variables like age and gender (p=0.098 and p=0.985). Conclusion: This study assessed the expression of HER2 in gastric carcinomas and we found a statistically significant expression in intestinal type gastric carcinomas than the diffuse type gastric carcinomas. There was no significant overexpression of HER2 protein regarding the clinicopathological variables like age and gender.

Foi selecionada uma amostra aleatória (334 indivíduos) de todos os pacientes diagnosticados com câncer de estômago no período de 1980 a 1995 no Instituto Nacional do Câncer, Rio de Janeiro, sendo revisados seus dados histopatológicos. A concordância entre os diagnósticos prévios e atuais quanto à Classificação de Lauren foi considerada substancial (kappa= 0,65). Baseando-se nesta classificação, observou-se um declínio estatisticamente não significativo das proporções de câncer gástrico de tipo intestinal em idosos (sessenta anos ou mais) de ambos os sexos (em homens, 41,0% no período de 1980-1985, 37,9% de 1986 a 1990 e 28,8% de 1991 a 1995; entre mulheres, as proporções foram, respectivamente de 41,4%, 31,5% e 15,2%). As proporções de câncer gástrico de tipo intestinal permaneceram relativamente estáveis para os pacientes menores de sessenta anos.This study draws a random sample (334 individuals) of all patients diagnosed with stomach cancer from 1980 to 1995 at the National Cancer Institute in Rio de Janeiro, Brazil, and reviews histopathological data. Agreement between previous and present classification of the histopathological material (Laurén's classification) was considered quite substantial (kappa = 0.65). Based on this classification, a statistically nonsignificant trend towards decline in the intestinal type of stomach cancer among older individuals (60 years old or older) from both genders was observed (males: 41.0% in 1980-1985, 37.9% in 1986-1990, and 28.8% in 1991-1995; females: 41.4%, 31.5%, and 15.2%, respectively). Proportions of the intestinal type among younger patients from both genders remained stable throughout the period.

Foi selecionada uma amostra aleatória (334 indivíduos) de todos os pacientes diagnosticados com câncer de estômago no período de 1980 a 1995 no Instituto Nacional do Câncer, Rio de Janeiro, sendo revisados seus dados histopatológicos. A concordância entre os diagnósticos prévios e atuais quanto à Classificação de Lauren foi considerada substancial (kappa= 0,65). Baseando-se nesta classificação, observou-se um declínio estatisticamente não significativo das proporções de câncer gástrico de tipo intestinal em idosos (sessenta anos ou mais) de ambos os sexos (em homens, 41,0% no período de 1980-1985, 37,9% de 1986 a 1990 e 28,8% de 1991 a 1995; entre mulheres, as proporções foram, respectivamente de 41,4%, 31,5% e 15,2%). As proporções de câncer gástrico de tipo intestinal permaneceram relativamente estáveis para os pacientes menores de sessenta anos.